By day 2 post-transfer, a striking phenotypic divergence was apparent between tumor-infiltrating and peripheral lymphoid organ DUC18 T cells, with regard to their CD25 and CD62L expression profiles (Figure 2B). This evidence concerns the gene SELL and neoplasm.